# Susceptibility and resistance of Gram-negative bacteria to a novel antimicrobial agent TGV-49

## TL;DR

This study explores TGV-49, a new antimicrobial agent, which shows strong effectiveness against drug-resistant Gram-negative bacteria with minimal resistance development.

## Contribution

The study introduces TGV-49 as a novel antimicrobial with low resistance potential against multidrug-resistant Gram-negative bacteria.

## Key findings

- TGV-49 effectively overcomes resistance to conventional antibiotics in Gram-negative bacteria.
- Experimental evolution showed minimal resistance development in Acinetobacter baumannii when exposed to TGV-49.
- TGV-49 is effective against both clinical and agricultural Gram-negative pathogens.

## Abstract

Antimicrobial resistance remains a major global public health challenge that necessitates novel drugs with a low resistance rate.

Herein, we evaluate TGV-49, a novel broad-spectrum antimicrobial agent, against multidrug-resistant Gram-negative bacteria, including ESKAPE pathogens (Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae) and pathogens from agriculture that infect humans (Ralstonia solanacearum and Aeromonas hydrophila).

TGV-49 was highly effective in overcoming resistance to conventional antibiotics. The experimental evolution of A. baumannii using a morbidostat revealed minimal development of resistance.

Our findings suggest TGV-49 as a potential alternative for combating MDR infections in clinical and agricultural settings.